Finch’s platform builds off of proven clinical efficacy, and leverages the principles of microbial ecology through Full-Spectrum Microbiota™ to restore the healthy microbiome. As an orally-administered product, CP101 contains the full complement of functional microorganisms offering the potential to help restore a dysbiotic microbiota (or microbial imbalance) to a normal, functioning gut microbial community.


Simpler, more convenient administration via capsule that avoids conventional invasive techniques (e.g. retention enema, nasogastric tube, colonoscopy or self-administered enema).

Full-Spectrum Therapeutic™

Harnesses broader microbiota diversity, which has been shown to produce fuller, more rapid restoration of gut flora.

Longer Shelf-Life

Novel processing method ensures longer product life and enhances commercial and distribution viability.

By successfully engrafting in the host microbiome, our Full-Spectrum Microbiota™ (FSM™) platform has the potential to generate therapies that cure disease, prevent future onset, improve patient health and enhance quality of life.



PRISM 3 (Preventing Recurrence of Clostridium difficile Infection using Full-Spectrum Microbiota™) is Finch’s clinical trial in patients with recurrent Clostridium difficile infection (CDI).

  • Company announced the patients had been dosed in June 2017
  • PRISM 3 is a multicenter, randomized, placebo-controlled trial to evaluate the efficacy and safety of CP101 in approximately 240 patients with recurrent CDI at clinical sites throughout the US
  • Primary endpoint is prevention of recurrence of CDI through eight weeks following administration of CP101, compared to placebo

The trial is actively enrolling patients. For more information on PRISM 3, please visit clinicaltrials.gov